Mold Illness and CIRS in NYC: A Comprehensive Integrative Approach
Few diagnoses are more frustrating for patients — and more frequently missed by conventional medicine — than Chronic Inflammatory Response Syndrome (CIRS). In New York City, where aging building stock, poor ventilation, and water intrusion events are common, mold-related biotoxin illness is a significant clinical reality. At Regen Health Physicians NYC (RHPNY), Dr. Ajit Dhaliwal applies a rigorous, evidence-based evaluation framework for patients presenting with multi-system symptoms potentially attributable to CIRS.
What Is CIRS?
Chronic Inflammatory Response Syndrome (CIRS) is an innate immune dysfunction triggered by exposure to biotoxins — primarily mycotoxins and actinomycetes produced in water-damaged buildings (WDB). The term was defined and systematized by Ritchie Shoemaker, MD, whose work established the neurological and inflammatory biomarker profile that characterizes the condition.
CIRS is not simply mold allergy. It reflects a genetically susceptible subset of the population (approximately 24% carry the HLA-DR genotype associated with impaired biotoxin clearance) in whom biotoxin exposure triggers a persistent inflammatory cascade that does not self-resolve after removing the exposure.
Common Symptoms
CIRS produces a diverse, overlapping symptom cluster that mimics many other conditions:
- Neurological: Brain fog, cognitive slowing, word-finding difficulties, disorientation
- Fatigue: Profound, post-exertional fatigue disproportionate to activity
- Respiratory: Shortness of breath, air hunger, sinus congestion
- Musculoskeletal: Diffuse aches, muscle cramping, joint pain without inflammation on imaging
- Sleep: Non-restorative sleep, night sweats
- GI: Nausea, abdominal pain, diarrhea
- Mood: Anxiety, depression, irritability
- Miscellaneous: Static shocks, light sensitivity, metallic taste
The hallmark of CIRS — and what distinguishes it from other conditions — is the multi-system nature of symptoms and the absence of a clear diagnosis from conventional evaluation.
How RHPNY Evaluates for CIRS
The Shoemaker Protocol provides a validated framework for CIRS diagnosis, which Dr. Dhaliwal adapts for clinical practice:
Step 1: Environmental Exposure History
Assessment of living and work environments for water damage, visible mold, musty odors, or known flooding events. NYC building inspections and ERMI testing may be recommended.
Step 2: Visual Contrast Sensitivity (VCS) Testing
The VCS test screens for neurological CIRS effects using a standardized visual pattern detection task. A positive (failed) VCS test correlates strongly with biotoxin-related neurological dysfunction.
Step 3: Biomarker Panel
A comprehensive CIRS panel includes:
- TGF-β1 — elevated in CIRS, drives fibrotic and inflammatory processes
- MMP-9 — elevated; mediates blood-brain barrier disruption
- VEGF — typically low in CIRS; reflects reduced tissue perfusion signaling
- MSH (α-melanocyte stimulating hormone) — typically low; MSH deficiency explains many CIRS symptoms
- VIP (Vasoactive Intestinal Polypeptide) — low; affects regulatory T-cell function
- C4a — elevated complement split product; amplifies inflammation
- ADH and osmolality — assess regulation disruption (explains CIRS-related thirst and urination patterns)
- HLA-DR typing — identifies genetic susceptibility
Step 4: Brain MRI with NeuroQuant (when indicated)
NeuroQuant volumetric MRI analysis documents the characteristic pattern of brain volume changes in CIRS — atrophy in specific regions correlating with symptom clusters.
Treatment: The Shoemaker Protocol Adapted
Phase 1: Removal from Exposure
No treatment works while active exposure continues. Identifying and remediating the water-damaged environment — or relocating — is the non-negotiable first step. This alone resolves symptoms in many mold-susceptible patients.
Phase 2: Binders
Cholestyramine (CSM) or Welchol (colesevelam) bind biotoxins in the GI tract, interrupting the enterohepatic recirculation that perpetuates CIRS. This is the foundational pharmacological step.
Phase 3: Sequential Biomarker Correction
The Shoemaker Protocol addresses CIRS biomarkers in a defined sequence:
- MMP-9 normalization
- VEGF correction
- C4a reduction
- MSH support
- VIP optimization (nasal VIP is prescribed in late-stage treatment)
At RHPNY, this protocol integrates with chronic disease management and, where indicated, peptide therapy to support immune regulation and tissue repair.
Phase 4: Restoration
Nutritional repletion, gut microbiome support, and addressing co-infections (Lyme, MARCoNS — multiply antibiotic resistant coagulase-negative staphylococcus) when present.
The RHPNY Difference
Many NYC physicians are unfamiliar with CIRS. At RHPNY, Dr. Dhaliwal applies a structured diagnostic and treatment framework for patients who have struggled with unexplained multi-system illness. This means patients receive an accurate assessment rather than years of misdiagnosis.
Book a consultation at RHPNY if you suspect mold illness or CIRS may be contributing to your symptoms.
---
This content is for educational purposes only and does not constitute medical advice. CIRS evaluation and treatment at RHPNY is individualized by Dr. Ajit Dhaliwal, MD, following a comprehensive clinical assessment. The Shoemaker Protocol referenced is a clinical framework; its implementation is adapted based on individual patient needs.
